Oppenheimer上调Tarsus股票目标价，对执行力和眼部玫瑰痤疮潜力印象深刻
Oppenheimer分析师Francois Brisebois解释了上调目标价的理由。评论重点关注了Tarsus Pharmaceuticals的产品XDEMVY的令人印象深刻的销售数据，特别强调了其在治疗眼部玫瑰痤疮方面的潜力。该公司展现了显著的增长，InvestingPro数据显示，过去十二个月的收入增长率高达802%。
Is Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?
We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...
Oppenheimer lifts Tarsus stock target, impressed by execution and ocular rosacea potential
Oppenheimer updated its outlook on Tarsus Pharmaceuticals (NASDAQ:TARS), a $1.8 billion market cap biotechnology company, ...
Tarsus制药重组董事会，任命新委员会主席
加利福尼亚州尔湾市 - 市值17.8亿美元的生物制品公司Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)根据最近向美国证券交易委员会提交的8-K文件，宣布了董事会成员和委员会任命的变更。
腾讯网7 天
WEEX WE-Launch上线TARS AI，投入WXT和TAI瓜分1.6万TAI
BlockBeats 消息，1 月 15 日，据 WEEX 交易平台公告，该平台已上线第 61 期 WE-Launch 项目 TARS AI (TAI)，用户于 1 月 19 日 22:00 UTC+8 之前投入 WXT 和/或 TAI，即可按有效投入占比瓜分 16,000 TAI 代币。WXT 奖池占比 70%，TAI 奖池占比 30%。投入的 WXT 和 TAI 不消耗，可同时参与其他项目或交 ...
Brokerages Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Target Price at $54.20
Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) have been assigned an average rating of “Buy” from the ...
Seeking Alpha4 年
TARS Tarsus Pharmaceuticals, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Tarsus Pharmaceuticals (TARS) Receives a Buy from Barclays
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report), with a ...
Tarsus Pharmaceuticals: Strong Market Penetration and Promising Expansion into Ocular Rosacea
Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Tarsus Pharmaceuticals (TARS – Research Report). The ...